NRG
54
2
LMT
49
-6
D
48
2
AXP
64
4
V
30
-10
C
71
3
NEM
61
-3
LEG
40
9
ED
43
-3
CFG
64
6
RF
61
4
HSY
32
-3
EL
43
-2
XOM
42
-2
URBN
56
-12
ZTS
16
-7
PNW
52
-3
GILD
46
-10
GOOGL
48
5
SEE
42
-2
NRG
54
2
LMT
49
-6
D
48
2
AXP
64
4
V
30
-10
C
71
3
NEM
61
-3
LEG
40
9
ED
43
-3
CFG
64
6
RF
61
4
HSY
32
-3
EL
43
-2
XOM
42
-2
URBN
56
-12
ZTS
16
-7
PNW
52
-3
GILD
46
-10
GOOGL
48
5
SEE
42
-2
Financhill
Back

BioMarin Pharmaceutical 10K Form

Buy
57

BMRN
BioMarin Pharmaceutical

Last Price:
$55.23
Seasonality Move:
3.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-04-26 10Q BMRN/BioMarin Pharmaceutical Quarterly
2024-02-26 10K BMRN/BioMarin Pharmaceutical Annual
2023-11-02 10Q BMRN/BioMarin Pharmaceutical Quarterly
2023-08-02 10Q BMRN/BioMarin Pharmaceutical Quarterly
2023-04-28 10Q BMRN/BioMarin Pharmaceutical Quarterly
2023-02-27 10K BMRN/BioMarin Pharmaceutical Annual

Receive BMRN News And Ratings

See the #1 stock for the next 7 days that we like better than BMRN

BMRN Financial Statistics

Sales & Book Value

Annual Sales: $2.9B
Cash Flow: $157.6M
Price / Cash Flow: 17.61
Annual Sales: $30.21
Price / Book: 1.83

Profitability

EPS (TTM): 2.69000
Net Income (TTM): $523.9M
Gross Margin: $2.3B
Return on Equity: 9.62%
Return on Assets: 7.5%

BioMarin Pharmaceutical Earnings Forecast

Key BioMarin Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 27 years for BMRN is 79.67%.
  • The Selling, General & Administrative Expenses for BMRN have been equal to 35.35% of Gross Profit Margin.
  • The Research & Development expenses have been 26.18% of Revenue.
  • The Interest Expense is 2.89% of Operating Income.
  • The Net Earning history of BMRN is 14.96% of Total Revenues.
  • Per Share Earnings over the last 27 years have been positive in 15 years.

BioMarin Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BMRN
CUSIP: 09061G
Website: biomarin.com

Debt

Debt-to-Equity Ratio: 0.1
Current Ratio: 5.52
Quick Ratio: 3.2

Price-to-Earnings

Trailing P/E Ratio: 25
Forward P/E Ratio: 10.22

BMRN Technical Analysis vs Fundamental Analysis

Buy
57
BioMarin Pharmaceutical (BMRN) is a Buy

Is BioMarin Pharmaceutical a Buy or a Sell?